<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2891200/" ref="ordinalpos=2602&amp;ncbi_uid=2553872&amp;link_uid=PMC2891200" image-link="/pmc/articles/PMC2891200/figure/F3/" class="imagepopup">Figure 3.  From: Targeting Eicosanoids <span class="highlight" style="background-color:">Pathway</span> in Non-Small Cell Lung Cancer. </a></div><br /><div class="p4l_captionBody">The increased understanding that selective COX-2 inhibitors are not free of unwanted side effects (particularly on renal and cardiovascular systems) have led to a reevaluation of other potential targets in the PG synthesis pathway downstream of COX for treatment and/or prevention of lung cancers, including PGE synthases and 15-PGDH. Another attractive target for inhibition of the activity of the PG synthesis pathway is inhibition of downstream receptor signaling.</div></div>